and HbA1c values (46.51 ± 16.15 mmoL/moL vs 52.15 ± 15.43 mmoL/moL, P < 0.001)was found in Group 1 but not in Group 2 (140.6 ± 47.87 mg/dL vs. 145.31 ± 30.18 mg/dL, P = 0.707, and 55.31 ± 20.58 mmoL/moL vs. 53.38 ± 9.49 mmoL/moL, P = 0.780). In Group 1, 20.7% of patients could reduce or suspend their antidiabetic therapy compared to none in Group 2 (P = 0.03), despite the significant weight increase observed in Group 1. SVR induced a significant amelioration of glycemic control in diabetic HCV-patients, despite a significant weight increase; larger prospective studies are needed to verify whether these results are maintained over the long-term.
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K E Y W O R D S
anti-hepatitis C virus DAA, hepatitis C virus, hepatitis virus Abbreviations: AH, arterial hypertension; ALT, alanine aminotransferase; APH, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CAD, coronary artery disease; CHC, chronic hepatitis C; CI, confidence interval; DAAs, direct-acting antivirals; EASL, european association for the study of the liver; ECG, electrocardiograms; FG, fasting glucose; GGT, gamma glutamyltranspeptidase; HbA1c, glycated hemoglobin; HC, hip circumference; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; IL28B, interleukin 28B; INHS, italian national health system; IQR, interquartile range; IR, insulin resistance; IRS, insulin receptors; KPa, kilopascal; MS, metabolic syndrome; OLT, orthotopic liver transplant; OR, odds ratio; RBV, ribavirin; SOC, suppressor of cytokines; SVR, sustained virologic response; TE, transient elastography; T2DM, type 2 diabetes mellitus; UKPDS, UK prospective diabetes study; US, ultrasound scan; WC, waist circumference; WHR, waist-to-hip ratio. The severity of liver fibrosis was determined within 3 months from treatment by transient elastography (TE) and patients were stratified according to METAVIR Scale. 28 An abdominal ultrasound (US) was performed in each patient at baseline and at the end of the study (EOS).
Baseline and EOS aliquoted plasma samples were stored at −80°C until assayed. Plasma insulin concentrations were assessed in patients who had never received antihyperglycemic agents by a double antibody Results were recorded in kilopascal (KPa); patients were fasting for a minimum of 6 h prior to TE. Values for each patient were calculated as median of a minimum of 10 consecutive measurements and exams with an interquartile range (IQR) divided by mean value (IQR/M) of >30% or a success rate of 60% were excluded as recommended by current guidelines. Patients were subsequently divided into four groups (F0-F1, F2, F3, F4) according to the METAVIR Scale. 28 Patients with cirrhosis underwent upper endoscopy within 3 months from the study inclusion in order to verify the presence of esophageal/gastric varices.
| Diabetic complications
Coronary artery disease (CAD) was assessed by a conventional 
| Statistical analysis
Patients' characteristics at baseline and at the end of follow-up were compared between groups using the Student t test for continuous variables and the chi-square (or Fisher's exact test), when expected cell frequencies were less than five for categorical variables. In particular, weight, waist and hips circumference, and biochemical changes were analyzed by paired t-test for the interval between baseline to 12 weeks after the end of therapy (up to 252 days from baseline). Association between predictor variables and glycemic control improvement were determined by odds ratio (OR) and 95% confidence interval (CI) calculated using Cox proportional hazards regression. Variables with P < 0.1 in the univariate model were included in the multivariate model.
| RESULTS
All patients included in the study protocol were Caucasian; Table 2 summarizes baseline demographic, anthropometric, and clinical characteristics of patients who achieved SVR (Group 1) and those who did not or who had not been treated (Group 2). Baseline liverrelated and diabetes-related features are reported in Table 3 Values of FG and HbA1c levels, antidiabetic medications and prevalence of macro/microangiopathic complications were comparable between the two groups (Table 3) . and at the end of the study are reported in Table 4 .
To verify whether ribavirin (RBV) might have influenced posttreatment HbA1c values through its hemolytic effect, we analyzed treated patients who achieved SVR according to the use of the medication: a significant decrease of HbA1c levels was observed both in 74 patients receiving RBV (P = 0.024) and in 27 patients not given RBV (P = 0.007).
Finally, in order to individuate predictive factors clinically relevant for glycemic amelioration (defined as a ≥20% decrease of HbA1c levels), we used a Cox proportional hazard risk model (Table 5 ). Based on a multivariable regression analysis, SVR was the only independent predictive factor associated with the improvement of glycemic control (OR = 49.75, 95% CI 2.197-112.67, P = 0.014).
| Weight and antidiabetic treatment changes
Among Group 1 patients, the mean weight change from baseline to SVR was +2.61 ± 6.13 kg (P = 0.023); no significant weight variation was observed in Group 2 patients (+0.26 ± 1.34 kg, P = 0.56).
Baseline to SVR, 63 of 101 (62.3%) sustained responders gained Retinopathy, n (%) 7 (6.9) 3 (14.3%) 0.374
Coronary artery disease, n (%) 2 (2%) 0 (0%) 1
Peripheral artery disease, n (%) 5 (5%) 0 (0%) 0.586
IL28B, interleukin 28B; GGT, gamma-glutamyltranspeptidase; HCC, epatocellular carcinoma; HbA1c, glycated hemoglobin; OHA, oral hypoglycemic agents. 
| DISCUSSION
In our study, clearance of HCV induced a significant improvement in glycemic control among 101 diabetic patients, as demonstrated by the reduction of FG and HbA1c levels 12 weeks after the end of treatment with DAAs. This result was obtained despite the weight gain observed in more than 60% of cured patients, suggesting that improved glycemic control was not due to lifestyle change. The weight increase found in our patients was surprising but not unexpected as it was already described by Azad et al. 35 who reported a significantly higher mean weight gain in diabetic patients compared to non-diabetics treated with sofosbuvir +ledipasvir (+5.8 ± 7.2 pounds vs. 1.9 ± 7.8 pounds, P = 0.03). The reason for the weight increase observed among diabetic patients with SVR is still unexplained; we can speculate that the awareness of being definetively cured for HCV might have induced a less stringent nutritional compliance in the responders. Our multivariate analysis did not reveal confounders in the association between SVR and glycemic control improvement, providing indirect support for a causal role of HCV in the induction of T2DM. The way whereby HCV induces T2DM is IR, 3 HCV was shown to impair the hepatocyte insulin signalling pathway by several ways, 36 including the stimulus to the production of tumor necrosis factor-α, the serine phosphorylation of the insulin receptors (IRS), the over-expression of the suppressor of cytokines (SOC-3), 37, 38 and the induction of SOC-7.
39
The mechanism through which DAAs therapy ± RBV ameliorates IR has not been fully established but it is most likely mediated via viral clearance, showing an inexorable decline in glucose control over time. 41 It is reasonable to hypothesize that a successful eradication of HCV would improve clinical outcomes in patients with T2DM as reported by a recent study 42 showing that in diabetic patients with CHC treated with IFN/RBV and followed up for more than 7 years, none of those who obtained SVR developed retinopathy and/or neuropathic symptoms.
Second, T2DM remains a strong risk factor for HCC development in cirrhotics after SVR has been obtained 43, 44 but a good glycemic control seems to reduce the incidence of HCC. 45, 46 Third, pre-OLT diabetes is associated with increased incidence of post-OLT mortality; 47 a recent study 48 showed that good glycemic control preoperatively may protect against the harmful effect of T2DM on infection and is associated with a reduced risk of readmission to intensive care unit and a reduced length of stay in hospital.
Our findings have some limitations: although statistically significant, our results are issued from a study including a relatively small and selected population of patients with HCV infection and mild T2DM and need to be confirmed by larger studies, including patients with severe T2DM of long duration. Moreover, before drawing definite conclusions, our study needs a longer follow up period in order to assess whether the results obtained by SVR regarding glycemic control are maintained over the long-term and-more important-if this improvement will have an impact on T2DM outcome. It is conceivable that among CHC patients, T2DM natural history may be influenced not only by viral clearance but also by genetic and lifestyle-related aspects, such as dietary habits, physical activity, and adherence to therapy. We still need to assess if viral eradication is "per se" a protection from T2DM complications or whether the abovementioned factors play anyway a pivotal role in the outcome of the disease.
Finally, the impact of baseline liver steatosis on post-SVR glycemic control was not studied and we were not able to report details regarding oral hypoglycemic agents.
In conclusion, a significant improvement of glycemic control was observed in diabetic patients with CHC who obtained SVR with a clinically meaningful de-escalation of antihyperglycemic therapy; these findings raise the question as to whether the HCV eradication may also impacts the future morbidity and mortality due to T2DM. For this reason, close T2DM follow up post-HCV treatment is warranted and large prospective studies are needed to validate these results.
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